How secure is gene remedy? Is there something “distinctive” about enterprise capital? And who’s going to run the FDA?
We focus on all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a major setback for Bluebird Bio’s gene remedy program with some assist from Akshay Sharma, a bone marrow transplant professional at St. Jude Kids’s Analysis Hospital. Then, STAT’s Kate Sheridan joins us to debate her deep dive into Flagship Pioneering, the superlatively profitable and incessantly grandiose enterprise agency behind Moderna. Lastly, we dig into what the long run would possibly maintain for a post-Trump FDA, which stays and not using a everlasting commissioner.
For extra on what we cowl, right here’s the most recent on Bluebird; right here’s the story on Flagship; right here’s extra on the race for FDA commissioner; right here’s the place you may subscribe to the First Opinion Podcast; and right here’s our full protection of the coronavirus pandemic.
Make sure to join on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.
And when you have any suggestions for us — subjects to cowl, friends to ask, vocal tics to stop — you may electronic mail [email protected].
Fascinated by sponsoring a future episode of “The Readout LOUD”? E mail us at [email protected].